Cangene Corporation  

(Public, TSE:CNJ)   Watch this stock  
Find more results for CNJ

Officers and directors

R. Craig Baxter
Chairman of the Board
John A. Sedor
President, Chief Executive Officer, Director
Jeffrey Lamothe
Chief Financial Officer
Gary Clyde Floyd
Chief Operating Officer
Laura Saward
Chief Scientific Officer
Michael D. Adelman
Vice President - Commercial Operations
Francis St. Hilaire
Vice President, General Counsel, Secretary
Les Deezar
Vice President - Human Resources
Chris Sinclair
Vice President - Strategic Planning
Kevin G. Taylor
Vice President - Business Development


155 Innovation Drive
+1-204-2754200 (Phone)
+1-204-2697003 (Fax)

Website links

Cangene Corporation (Cangene) is a biopharmaceutical company in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates in two segments: biopharmaceutical operations and contract services. The biopharmaceutical operations segment consist of sales of approved products and non- specialty plasma. The contract-services segment consists of third-party contract-manufacturing revenues at the Company’s Winnipeg facilities, as well as at Cangene bioPharma in Baltimore. It also provides commercial contract-manufacturing services, primarily through a United States-based subsidiary. The Company’s products include Rho(D) Immune Globulin (Human) for Injection (WinRho) SDF, Hepatitis B Immune Globulin (Human) Injection (HepaGam B) and Varicella Zoster Immune Globulin (Human) (VariZIG). In February 2014, Emergent BioSolutions Inc completed the acquisition of Cangene.

Related companies

* Delayed by up to 20 minutes -  Disclaimer